Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levorphanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 9/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 9/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 8/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 8/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 8/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 8/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 5/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SCN1A | P35498 | 2/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 2/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levorphanol SCHEMBL5171217 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL24335 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL16310821 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL3495833 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL21095576 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL12232844 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL22791693 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL22722062 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Dextrorphan SCHEMBL20535964 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemorphan SCHEMBL46201 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527858-B2 | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | MALLINCKRODT LLC (US) | 2016-12-27 | — | — | US | disclosed |
| US-9518062-B2 | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | MALLINCKRODT LLC (US) | 2016-12-13 | — | — | US | disclosed |
| US-8987291-B2 | Opioid-containing oral pharmaceutical compositions and methods | Upsher Smith Laboratories, Inc. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8921386-B1 | Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties | PISGAH LABORATORIES, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140370006-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | SpecGx LLC | 2014-12-18 | — | — | US | disclosed |
| US-20140370005-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | SpecGx LLC | 2014-12-18 | — | — | US | disclosed |
| US-8829020-B2 | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | MALLINCKRODT LLC (US) | 2014-09-09 | — | — | US | disclosed |
| US-8748416-B1 | Opioid salts and formulations exhibiting anti-abuse and anti-dumping properties | PISGAH LABORATORIES, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8569330-B1 | Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties | PISGAH LABORATORIES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569329-B1 | Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties | PISGAH LABORATORIES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8476291-B1 | Opioid salts and formulations exhibiting anti-abuse and anti-dumping properties | PISGAH LABORATORIES, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130123293-A1 | OPIOID-CONTAINING ORAL PHARMACEUTICAL COMPOSITIONS AND METHODS | UPSHER-SMITH LABORATORIES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8338444-B1 | Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties | PISGAH LABORATORIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123293-A1 | OPIOID-CONTAINING ORAL PHARMACEUTICAL COMPOSITIONS AND METHODS | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885GRIN1 401/4885GRIN2A 374/4885 |
| US-20140370006-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | VEGFA, OPRL1, OGFR | OPRM1 5/4885GRIN1 3441/4885GRIN2A 2767/4885 |
| US-20140370005-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | VEGFA, OPRL1, OGFR | OPRM1 5/4885GRIN1 3441/4885GRIN2A 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.